Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major ...

In announcing the results, Novo Nordisk said Rybelsus, an oral glucagon-like peptide-1 (GLP-1) receptor agonist already ...

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with T2D.

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...

Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.

The medicine, which Novo sells as Rybelsus, cut the risk of cardiovascular complications by 14% when added to standard therapies in people with diabetes and heart disease.

Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Novo Nordisk A/S (NVO) announced Monday the headline results from the SOUL cardiovascular outcomes trial, which achieved its primary ...

You’ve probably heard of the semaglutide brand names Ozempic®, Wegovy, and Rybelsus. You may have even heard about affordable options like compounded semaglutide.